Last reviewed · How we verify
epoetin alfa or beta
epoetin alfa or beta is a erythropoiesis-stimulating agent Small molecule drug developed by Hoffmann-La Roche. It is currently in Phase 3 development for Anemia associated with chronic kidney disease, Anemia associated with chemotherapy. Also known as: Epoetin.
Epoetin alfa and beta stimulate erythropoiesis by binding to the erythropoietin receptor.
Epoetin alfa and beta stimulate erythropoiesis by binding to the erythropoietin receptor. Used for Anemia associated with chronic kidney disease, Anemia associated with chemotherapy.
At a glance
| Generic name | epoetin alfa or beta |
|---|---|
| Also known as | Epoetin |
| Sponsor | Hoffmann-La Roche |
| Drug class | erythropoiesis-stimulating agent |
| Target | erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Epoetin alfa and beta are recombinant forms of human erythropoietin, a hormone that promotes the production of red blood cells. They work by binding to the erythropoietin receptor on the surface of erythroid progenitor cells, triggering a signaling cascade that leads to the proliferation and differentiation of these cells into mature red blood cells.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia associated with chemotherapy
Common side effects
- Thromboembolism
- Hypertension
- Headache
- Fatigue
- Nausea
Key clinical trials
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Vafseo Outcomes In-Center Experience (PHASE3)
- A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia. (PHASE3)
- A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia (PHASE3)
- A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis (PHASE3)
- Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants (PHASE3)
- Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis. (PHASE2)
- A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- epoetin alfa or beta CI brief — competitive landscape report
- epoetin alfa or beta updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI
Frequently asked questions about epoetin alfa or beta
What is epoetin alfa or beta?
How does epoetin alfa or beta work?
What is epoetin alfa or beta used for?
Who makes epoetin alfa or beta?
Is epoetin alfa or beta also known as anything else?
What drug class is epoetin alfa or beta in?
What development phase is epoetin alfa or beta in?
What are the side effects of epoetin alfa or beta?
What does epoetin alfa or beta target?
Related
- Drug class: All erythropoiesis-stimulating agent drugs
- Target: All drugs targeting erythropoietin receptor
- Manufacturer: Hoffmann-La Roche — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Anemia associated with chronic kidney disease
- Indication: Drugs for Anemia associated with chemotherapy
- Also known as: Epoetin
- Compare: epoetin alfa or beta vs similar drugs
- Pricing: epoetin alfa or beta cost, discount & access